The anti-apoptotic protein BCL2 has been proposed as an attractive therapeutic target both to prevent resistance to AR inhibition in AR-dependent PC, and to target AR-independent neuroendocrine mCRPC (13, 18). This evidence concerns the gene BCL2 and pachyonychia congenita.